Observational Study About Patients Diagnosed With NAFLD

Study on the Characteristic, Therapy and Prognosis of Patients With Nonalcoholic Fatty Liver Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05625750

Enrollment

500

Registered

2022-11-23

Start date

2022-04-27

Completion date

2027-04-27

Last updated

2022-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease

Keywords

Nonalcoholic Fatty Liver Disease

Brief summary

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Detailed description

Patients with NAFLD were recruited in the current study and divided into NAFLD group, and NASH group. The researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to ALT, AST, TG, TC, etc. Characteristic and prognosis of patients will be recorded. The serum, feces, urine and liver (if necessary) samples of all subjects will be taken after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

1\. patients diagnosed with nonalcoholic fatty liver disease

Exclusion criteria

1. patients suspected of excessive alcohol consumption 2. malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation 3. incomplete data such as HBV serological results and abdominal ultrasound results 4. patients who refuse to sign informed consent

Design outcomes

Primary

Measure	Time frame	Description
BMI	3 weeks	BMI stands for body mass index. This is the ratio of a person's height to their weight.
alcohol intake	3 years	alcohol consumption every week

Countries

China

Contacts

Primary ContactYan Huang

ganrankedrhyan@163.com+86 13874854142

Outcome results